BACKGROUND: Colistin-resistant/carbapenem-resistant Acinetobacter baumannii is a significant challenge for antibiotic treatment and infection control policies. Since 2012, in Central Greece an increase of colistin/pan- resistant A. baumannii has occurred, indicating the need for further analysis. METHODS: A total of 86 colistin-resistant/carbapenem-resistant out of 1228 A. baumannii clinical isolates, consecutively collected between 2012 and 2014 in a tertiary Greek hospital of Central Greece, as well as one environmental isolate from surveillance cultures were studied. Molecular typing and mechanisms of resistance to colistin and to carbapenems were assessed, whereas, epidemiological and clinical data of the patients were reviewed. RESULTS: During the study period, the rate of colistin resistance gradually increased and reached 21.1 % in 2014. All colistin-resistant/carbapenem-resistant A. baumannii belonged to 3LST ST101 clone that corresponds to the international clonal lineage II. Carbapenem resistance was associated with the presence of bla oxa-23-like, while resistance to colistin probably correlated with G54E and R109H amino acid substitutions in PmrA and PmrC, respectively. CONCLUSIONS: Epidemiological data of the patients indicated that the first detection of colistin-resistant/carbapenem-resistant ST101 clone in the University Hospital of Larissa (UHL) was associated with a patient who previously had received colistin, while, the movement of the infected patients into the hospital probably resulted to its spread.

Department of Critical Care Medical School University of Thessaly Larissa Greece

Department of Medicine Medical School University of Thessaly Larissa Greece

Department of Microbiology Medical School University of Thessaly Larissa Greece

Department of Microbiology University Hospital of Larissa Larissa Greece

Faculty of Medicine and University Hospital in Plzen Charles University Prague Plzen Czech Republic

Zobrazit více v PubMed

Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev. 1996;9:148–65. PubMed PMC

Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 2011;6:407–22. doi: 10.2217/fmb.11.23. PubMed DOI

Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3471–84. doi: 10.1128/AAC.01464-06. PubMed DOI PMC

Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36. doi: 10.1111/j.1469-0691.2006.01456.x. PubMed DOI

Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–51. doi: 10.1038/nrmicro1789. PubMed DOI

Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis. 2002;35:901–2. doi: 10.1086/342570. PubMed DOI

Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10:917–34. doi: 10.1586/eri.12.78. PubMed DOI

Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60:1295–303. PubMed PMC

Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004) Clin Microbiol Infect. 2006;12:315–21. doi: 10.1111/j.1469-0691.2005.01351.x. PubMed DOI

Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188–91. doi: 10.1016/j.diagmicrobio.2009.05.019. PubMed DOI

Park YK, Choi JY, Jung SI, Park KH, Lee H, Jung DS, et al. Two distinct clones of carbapenem resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn Microbiol Infect Dis. 2009;64:389–95. doi: 10.1016/j.diagmicrobio.2009.03.029. PubMed DOI

Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, Poulou A, et al. Spread of a carbapenem-and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect. 2014;86:260–6. doi: 10.1016/j.jhin.2014.02.001. PubMed DOI

Choi JY, Ko EA, Kwon KT, Lee S, Kang CI, Chung DR, et al. Acinetobacter sp. isolates from emergency departments in two hospitals of South Korea. J Med Microbiol. 2014;63:1363–8. doi: 10.1099/jmm.0.075325-0. PubMed DOI

Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643. doi: 10.3389/fmicb.2014.00643. PubMed DOI PMC

Pogue JM, Cohen DA, Marchaim D. Editorial commentary: polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis. 2015;60:1304–7. PubMed PMC

Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–7. doi: 10.1128/AAC.00834-10. PubMed DOI PMC

Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3022–4. doi: 10.1128/AAC.01732-10. PubMed DOI PMC

Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two component system. Antimicrob Agents Chemother. 2009;53:3628–34. doi: 10.1128/AAC.00284-09. PubMed DOI PMC

Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55:3370–9. doi: 10.1128/AAC.00079-11. PubMed DOI PMC

Park YK, Lee JY, Ko KS. Transcriptomic analysis of colistin-susceptible and colistin-resistant isolates identifies genes associated with colistin resistance in Acinetobacter baumannii. Clin Microbiol Infect. 2015;21(8):e1–7. PubMed

Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing; Twenty-First Information Supplement, CLSI document M100-S21. Wayne, PA: CLSI; 2012.

Clinical and Laboratory Standards Institute . Performance Standards for Antimicrobial Susceptibility testing; 23rd International Supplement, CLSI document M100-S23. Wayne, PA: CLSI; 2013.

Jones RN, Anderegg TR, Swenson JM, Quality Control Working Group Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol. 2005;43:925–7. doi: 10.1128/JCM.43.2.925-927.2005. PubMed DOI PMC

Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin Microbiol Infect. 2007;13:807–15. doi: 10.1111/j.1469-0691.2007.01759.x. PubMed DOI

Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother. 2005;49:4485–91. doi: 10.1128/AAC.49.11.4485-4491.2005. PubMed DOI PMC

American Thoracic Society. Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416. doi: 10.1164/rccm.200405-644ST. PubMed DOI

Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control. 1988;16:128–40. doi: 10.1016/0196-6553(88)90053-3. PubMed DOI

Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infection in the acute care setting. Am J Infect Control. 2008;36:309–32. doi: 10.1016/j.ajic.2008.03.002. PubMed DOI

Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species. Am J Infect Control. 2010;38:S25–33. doi: 10.1016/j.ajic.2010.04.196. PubMed DOI

Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74:1315–33. doi: 10.1007/s40265-014-0267-8. PubMed DOI PMC

Solomennyi A, Goncharov A, Zueva L. Extensively drug-resistant Acinetobacter baumannii belonging to the international clonal lineage I in a Russian burn intensive care unit. Int J Antimicrob Agents. 2015;45:525–8. doi: 10.1016/j.ijantimicag.2014.10.017. PubMed DOI

Teo J, Lim TP, Hsu LY, Tan TY, Sasikala S, Hon PY, et al. Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control. 2015;4:2. doi: 10.1186/s13756-015-0043-x. PubMed DOI PMC

Azimi L, Talebi M, Pourshafie MR, Owlia P, Rastegar LA. Characterization of carbapenemases in extensively drug resistance Acinetobacter baumannii in a burn care center in Iran. Int J Mol Cell Med. 2015;4:46–53. PubMed PMC

Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11–25. doi: 10.1016/j.ijantimicag.2004.10.001. PubMed DOI

Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208:1142–51. doi: 10.1093/infdis/jit293. PubMed DOI

Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2003;30:257–63. doi: 10.1086/595977. PubMed DOI

Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment. Diagn Microbiol Infect Dis. 2014;79:362–6. doi: 10.1016/j.diagmicrobio.2014.03.027. PubMed DOI

WHONET Greece (last update 17-12-2014). http://www.mednet.gr/whonet.

Liakopoulos A, Miriagou V, Katsifas EA, Karagouni AD, Daikos GL, Tzouvelekis LS, et al. Identification of OXA-23-producing Acinetobacter baumannii in Greece 2010 to 2011. Euro Surveill. 2012;17:11. PubMed

Mavroidi A, Likousi S, Palla E, Katsiari M, Roussou Z, Maguina A, et al. Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013. J Med Microbiol. 2015;64:993–7. doi: 10.1099/jmm.0.000127. PubMed DOI

Crombach WH, Dijkshoorn L, van Noort-Klaassen M, Niessen J, van Knippenberg-Gordebeke G. Control of an epidemic spread of a multi-resistant strain of Acinetobacter calcoaceticus in a hospital. Intensive Care Med. 1989;15:166–70. doi: 10.1007/BF01058568. PubMed DOI

Luo TL, Rickard AH, Srinivasan U, Kaye KS, Foxman B. Association of blaOXA-23 and bap with the persistence of Acinetobacter baumannii within a major healthcare system. Front Microbiol. 2015;6:182. PubMed PMC

Complete Nucleotide Sequences of mcr-4.3-Carrying Plasmids in Acinetobacter baumannii Sequence Type 345 of Human and Food Origin from the Czech Republic, the First Case in Europe